The peptide Library.

The foundation of any "recover better" stack. BPC-157 and TB-500 are the cornerstone duo; the rest extend or specialize the same machinery.

Peptides that turn down the volume on inflammation — useful for gut issues, skin conditions, chronic infections.

These push your pituitary to release its own GH in pulses. Mix a GHRH (CJC, Tesa, Sermorelin) with a GHRP (Ipa, Hexarelin, GHRP-2/6) for the synergistic effect — neither does much alone.

These bypass the pituitary and signal directly at IGF-1 or related anabolic receptors. Stronger and more pointed than the secretagogues, with bigger trade-offs.

Libido, arousal, and natural HPG-axis support. The melanocortins (PT-141, MT1, MT2) work centrally; Kisspeptin and Enclomiphene restore upstream hormone signaling.

Russian-origin nootropics dominate this category. The N-acetylated forms are stable upgrades of the originals; P21 is the experimental neurogenic outlier.

Thymic peptides for T-cell maturation, antiviral defense, and post-infection recovery. The Khavinson immune trio (Thymalin, Thymogen, Vilon) overlaps but each has a different center of gravity.

Epitalon is the flagship; FOXO4-DRI is the experimental senolytic; Humanin is the emerging mitochondrial-protective option.

Energy production, fat oxidation, antioxidant defense. Run MOTS-C as a "primer" cycle before tissue-repair stacks to clean up mitochondrial function first.

The incretin and incretin-plus class. Semaglutide is the conservative baseline, Tirzepatide the standard upgrade, Retatrutide the strongest emerging option. Cagrilintide is the amylin booster you add to extend effects.

Russian-developed tetrapeptides targeted at specific organ tissues. Mechanism is largely epigenetic gene-expression modulation. Common protocol across all: 20 mg vial reconstituted with 4 mL bac water = 5 mg/mL, 0.5–1 mg subQ daily (10 units = 0.5 mg), 10–20 day course 1–2× per year, AM, short half-life. Side-effect profile is uniformly mild.

Topical-only research peptides for compounding into creams and serums. None of these get injected — formulate at the stated concentrations into a base (HA, niacinamide serum, simple cream).

Why combine peptides? The right combo hits complementary mechanisms with the same dosing schedule — a single shot that delivers both peptides at their ideal frequency. The wrong combo forces one peptide into a sub-optimal protocol just so they can share a vial.

Why combine peptides? The right combo hits complementary mechanisms with the same dosing schedule — a single shot that delivers both peptides at their ideal frequency. The wrong combo forces one peptide into a sub-optimal protocol just so they can share a vial. The classic example: BPC-157 wants daily injections, but TB-500 only needs twice a week. A BPC + TB blend means you're injecting TB daily — not harmful, just wasteful, and not how TB was actually studied. You're paying for the convenience of one shot with a less-efficient TB schedule. Each combo below carries one of two tags. Optimal dose means the blend respects both peptides' ideal frequency and dosing. Non-optimal · Convenient means you're trading dosing efficiency for one-shot simplicity — the alternative (separate vials, separate schedules) is noted in each entry. Ipamorelin + CJC-1295 No DACSingle vial · 20 mgOptimal dose GHRP + GHRH synergy. A GHRP alone gives a weak pulse; a GHRH alone gives nothing without the GHRP signal. Together: ~5–10× the GH pulse of either alone, with physiologic pulse shape. Both peptides are taken at the same time (pre-bed, fasted) at matching doses — perfect blend candidate. BenefitsStronger GH/IGF-1 elevation than either solo; better sleep; improved body composition over months. Dose200–300 mcg of each per shot. Reconstitute20 mg vial (10/10) + 2 mL bac water = 5 mg/mL of each. 6 units = 300 mcg of each. Schedule5 days on / 2 off, 12–16 weeks. TimingPre-bed fasted (best), or post-workout, or AM fasted. Not within 2 hours of food. Selank + SemaxSingle vial · 10 mgOptimal dose Calm-focus pairing. Selank delivers non-sedating anxiolytic effects; Semax is a fast-acting nootropic / BDNF elevator. Same intranasal route, same daily dosing, complementary effects — frequently combined in Russian clinical literature. BenefitsReduced anxiety with sharpened focus — better than either alone for high-stress cognitive work. Dose1–2 intranasal sprays daily (~100–300 mcg of each). Reconstitute10 mg vial (5/5) + 2 mL bac water decanted into a 5–10 mL nasal sprayer. 1 spray ≈ 100 mcg of each. Schedule14–30 day cycles, 2–3× per year. TimingAM, or 30 min before stressful cognitive work. BPC-157 + TB-500Single vial · 20 mgNon-optimal · Convenient BPC drives anti-inflammatory and angiogenic signaling; TB drives actin / cell migration. Together they cover both major repair axes — the most evidence-supported pairing in the healing category. The catch is dosing frequency: BPC wants daily, TB wants twice a week, but the blend forces one schedule. BenefitsFaster, more comprehensive soft-tissue repair than either alone. Convenient single injection during an injury-repair cycle. Dose5–10 units daily, delivering 250–500 mcg of each. Reconstitute20 mg vial (10/10) + 2 mL bac water = 5 mg/mL of each. 5 units = 250 mcg of each; 10 units = 500 mcg of each. ScheduleDaily, 4–8 week cycle. TimingAnytime; near injury site if local. What optimal looks likeSeparate vials. BPC-157 daily at 250 mcg (or split AM/PM at 250 mcg each). TB-500 separately at 5 mg twice a week — the dose and frequency TB was actually studied at. The blend is fine for short healing cycles where one shot beats two; the cost is that TB is being injected far more often than necessary. GLOW — GHK-Cu + BPC-157 + TB-500Single vial · 70 mgNon-optimal · Convenient Aesthetic + repair stack. GHK-Cu drives collagen / skin / hair; BPC + TB cover tissue repair. One injection delivers all three. Same TB-frequency tradeoff as BPC + TB. BenefitsSkin glow, hair density, and joint / soft-tissue repair — concurrent. Dose~25 units daily, delivering ~2.5 mg GHK + 500 mcg BPC + 500 mcg TB. Reconstitute70 mg vial (50/10/10) + 5 mL bac water = 10 mg/mL GHK + 2 mg/mL BPC + 2 mg/mL TB. 25 units = 2.5 mg GHK + 500 mcg BPC + 500 mcg TB. ScheduleDaily, 6–8 weeks. TimingPre-bed. What optimal looks likeGHK-Cu daily at 1–2 mg and BPC-157 daily at 250 mcg work fine in this blend. TB-500 is the compromise — at 500 mcg/day in the blend, you're getting ~3.5 mg/week vs. the proper 10 mg/week (5 mg × 2). For the most efficient TB protocol, run TB separately at 5 mg twice weekly alongside a daily GHK + BPC stack. KLOW — KPV + GHK-Cu + BPC-157 + TB-500Single vial · 80 mgNon-optimal · Convenient GLOW + KPV. Adds gut/skin anti-inflammatory action via KPV's α-MSH mechanism — covers inflammation, repair, and aesthetics in one injection. Of all the healing blends, this one comes closest to dose-balanced for daily injection. BenefitsComprehensive recovery in one shot: gut, skin, joints, soft tissue. Dose~10 units daily, delivering ~250 mcg KPV + 1.25 mg GHK + 250 mcg BPC + 250 mcg TB. Reconstitute80 mg vial (10/50/10/10) + 4 mL bac water = 2.5 mg/mL KPV + 12.5 mg/mL GHK + 2.5 mg/mL BPC + 2.5 mg/mL TB. 10 units = 250 mcg KPV + 1.25 mg GHK + 250 mcg BPC + 250 mcg TB. ScheduleDaily, 6–8 weeks. TimingAnytime. What optimal looks likeKPV, GHK, and BPC all land near their typical daily dose at the standard KLOW unit — this is the most balanced of the healing blends. The TB tradeoff remains: 250 mcg/day in the blend = ~1.75 mg/week vs. the proper 10 mg/week. To run TB optimally, pull it out into a separate vial and dose 5 mg twice weekly while keeping KLOW for the daily KPV+GHK+BPC delivery. TB-500 + BPC-157 + KPVSingle vial · 30 mgNon-optimal · Convenient KLOW without the copper. Anti-inflammatory + repair without GHK-Cu accumulation concerns — useful if you already run topical GHK-Cu separately. BenefitsPure repair + anti-inflammation; lighter than KLOW. Dose~8 units daily, delivering ~270 mcg of each. Reconstitute30 mg vial (10/10/10) + 3 mL bac water = 3.33 mg/mL of each. 8 units = 267 mcg of each. ScheduleDaily, 6–8 weeks. TimingAnytime. What optimal looks likeBPC and KPV at ~250 mcg daily are reasonable, but TB at 267 mcg daily = ~1.85 mg/week vs. the proper 10 mg/week target. For efficient TB, separate it out: BPC + KPV in a daily 2-way blend (or separate vials), TB-500 alone at 5 mg twice weekly.

Which peptides go first, which follow, and what to do once a cycle ends. Running everything at once is rarely the right move.

Which peptides go first, which follow, and what to do once a cycle ends. Running everything at once is rarely the right move. The catalogue above tells you what each peptide does. This section is about order. A handful of principles cover most situations: prime the system before you tax it, clean before you repair, calm inflammation before you rebuild structure, and always cycle off long enough to stay sensitive. Below are the sequences that come up most often, then a sample year showing how they fit together. Prime, then build MOTS-C → repair or fat-loss stack Run a MOTS-C cycle for ~4 weeks before a tissue-repair stack (GLOW / KLOW / BPC+TB) or a fat-loss phase. MOTS-C tunes up mitochondrial function and insulin sensitivity, so the cells you're about to ask to repair tissue or burn fat are already working efficiently. Clean the engine, then ask more of it. Weeks 1–4: MOTS-C, 2–3× weekly — the primer. Week 5 onward: start the repair or fat-loss stack while MOTS-C tapers to maintenance or stops. Clean, then repair LL-37 → ARA-290 These send opposing immune signals, so they run in sequence, never together. LL-37 first to clear pathogens and biofilms; then ARA-290 to quiet the nervous system and repair what's left. Trying to "clean" and "calm" at the same time just cancels out. Weeks 1–2: LL-37 pulse — the deep clean. Then stop. Weeks 3–6: ARA-290 — the repair and nervous-system reset. Same logic applies more loosely whenever you're clearing an infection or gut overgrowth before a rebuild: knock down the bad actors first, then switch to repair mode. Cool, then mend KPV first (or alongside) for "hot" injuries If an injury is hot, throbbing, or angry, the inflammatory storm blunts BPC-157 and TB-500. Lead with a few days of KPV to take the heat out, then bring in the structural-repair peptides — or run KPV alongside them from the start. (The KLOW blend bakes this in by including KPV from day one.) Build, then consolidate GH and anabolic blocks are finite, not forever Growth-hormone stacks (Ipamorelin + CJC) run in 12–16 week blocks followed by ~4 weeks off so the pituitary resensitises. The strong anabolics (IGF-1 LR3, Follistatin) are deliberately short 4-week pulses for the same reason — and because the risk climbs the longer you run them. After a build block, drop to maintenance or rotate to a different modality rather than simply re-dosing into a desensitised system. Suppress, then restore Recover the hormone axis after anything that shut it down After a cycle that suppresses natural testosterone — or any time the HPG axis needs restarting — Kisspeptin and Enclomiphene restart the system from the top. Run them as a dedicated recovery block after the suppressive protocol ends, not during it. A sample year How the cycles fit on a calendar Most of these are short seasonal courses, not continuous use. A sane annual rhythm leaves recovery gaps between the heavy lifters: Late winter (Feb–Mar): MOTS-C primer → spring repair stack (BPC + TB, or GLOW / KLOW). Lines up with the classic "March" TB-500 course. Spring (Apr–Jun): a GH block (Ipa + CJC, 12–16 weeks) if building is the goal. Summer: lighter — maintenance only, or a melanotan tanning load with planned UV. Early autumn (Sep): second TB-500 / repair course; an LL-37 → ARA-290 "clean and repair" sequence to reset after summer. Late autumn / winter: immune and longevity courses — Thymogen or Thymalin through cold-and-flu season, an Epitalon course for sleep and biomarkers. The point isn't this exact calendar — it's spacing the demanding stacks apart, pulsing the longevity and immune peptides a couple of times a year, and never running two resensitisation-dependent stacks back to back.

What not to put in the same protocol — combinations that are redundant, that cancel each other out, that stack risk, or that are flatly unsafe given a condition.

What not to put in the same protocol — combinations that are redundant, that cancel each other out, that stack risk, or that are flatly unsafe given a condition. Three kinds of bad combination show up again and again: redundancy (two peptides fighting over the same receptor, so the second adds cost and side effects but no extra effect), opposing signals (two peptides pulling the body in contradictory directions), and additive risk (two peptides whose side effects compound). On top of those sit a few hard stops tied to your health status, not to another peptide. One GHRH at a timeTesamorelin, CJC-1295 (DAC or No-DAC), and Sermorelin are all GHRH analogs hitting the same receptor — running two together is pure redundancy. You pay twice and pile on side effects (water retention, glucose issues) for no extra GH. Pick one GHRH and pair it with one GHRP. This is exactly why the old Tesa + CJC + Ipa "triple stack" gets trimmed to Tesa or CJC, plus Ipamorelin. Don't pile up GHRPs eitherIpamorelin, GHRP-2, GHRP-6, and Hexarelin all compete at the same ghrelin / GH-secretagogue receptor. Stacking them doesn't add up — they jostle for the same door, and the extra cortisol, prolactin, and faster desensitisation outweigh any benefit. One GHRP per protocol. Never run two GLP drugs at onceSemaglutide, Tirzepatide, Retatrutide, Mazdutide, and Survodutide all act on the GLP-1 axis. Doubling them doesn't double weight loss — it multiplies the GI shutdown, hypoglycemia, and lean-mass loss. Run one incretin at a time; if you want more effect, titrate the one you're on or switch, don't add a second. LL-37 and ARA-290 — sequence, never simultaneousLL-37 ramps the immune system up to attack pathogens; ARA-290 calms it down to repair. Run together, they cancel out and waste both. Finish LL-37 first, then start ARA-290 (see Sequencing → "Clean, then repair"). Go easy on immune stimulators if you're autoimmuneLL-37 and the thymic peptides (Thymosin Alpha-1, Thymalin, TP-5, Thymogen) push immune activity up — which can flare an autoimmune condition (Hashimoto's, RA, psoriasis, lupus, and so on). If that's you, these need real caution, and stacking several of them on an already-overactive immune system is asking for trouble. ARA-290, which quiets immune over-activity, is the more sensible direction. Don't combine Melanotan II and PT-141Both are melanocortin agonists (PT-141 was carved out of MT2), so together the nausea, blood-pressure spikes, and priapism risk stack rather than add anything useful. Want the tan? MT2 alone already carries a libido effect. Want libido? PT-141 alone is the cleaner tool. Watch compounding hypoglycemiaIGF-1 LR3 drops blood sugar hard — eat carbs before injecting. Stacking it with other glucose-lowerers (AICAR, a strong GLP drug, fasted training, or insulin) can compound into a real hypo. Don't run IGF-1 alongside another aggressive glucose-lowering agent without carbs on hand and monitoring. Hard stop: pro-growth peptides + active or undiagnosed cancerIGF-1 LR3, MGF / PEG-MGF, the GH secretagogues, GHK-Cu, and TB-500 (cell-migration) all promote proliferation or angiogenesis — exactly what you don't want feeding a tumour. With an active, suspected, or recently treated malignancy, these are off the table until an oncologist clears you. Epitalon's telomerase activation carries the same theoretical caution around pre-cancerous cells. Mind frequency mismatches in shared vialsBlending peptides with different ideal schedules forces one onto the wrong cadence — the BPC-157 (daily) vs TB-500 (2× weekly) problem covered in Combos. Not unsafe, just inefficient. If optimal dosing matters more than one-shot convenience, separate the mismatched peptides into their own vials. Worked example — if you're running Retatrutide What adds nothing, and what actually works against it A triple agonist already maxes out appetite suppression and fat-burning. Most things people are tempted to bolt on are redundant, and a few pull in the wrong direction: Counteracts it — GHRP-6. Its whole job is to stimulate appetite. Bolting it onto a drug whose whole job is to kill appetite is self-defeating. No real value — a second fat-loss tool. Adding Tesamorelin or AOD-9604 for "extra" fat loss is largely redundant with what Reta already does, and Tesa piles glucose-intolerance risk onto a drug already stressing metabolism. Dangerous — a second incretin. Stacking Semaglutide or Tirzepatide on top is just doubling the same axis (see above). Don't. Genuinely useful — muscle preservation. The real risk on aggressive GLP weight loss is losing lean mass. Resistance training plus enough protein is the answer; a light GH-secretagogue block can help; and Cagrilintide is the one intentional pairing — it deepens loss and eases nausea. Watch combined hypoglycemia. Built from Verified Peptides + Go Alpha Labs catalogues + research literature. Now includes sequencing (order of operations) and conflict / do-not-mix flags. Informational reference only — not medical advice.

Pre-mixed vials. A blend isn't a different kind of peptide — it's the same compounds bought together, so it's one shot instead of three. The trade is flexibility: the ratio is fixed by the vial, so you scale everything at once.